Related Experiment Video
Updated: Nov 23, 2025

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
Published on: November 11, 2022
Hypokalemia in Patients with COVID-19
Gaetano Alfano1,2,3, Annachiara Ferrari4, Francesco Fontana5
1Surgical, Medical and Dental Department of Morphological Sciences, Section of Nephrology, University of Modena and Reggio Emilia, via del Pozzo 71, 41124, Modena, Italy. gaetano.alfano@unimore.it.
Insights
Hypokalemia, a common electrolyte imbalance in COVID-19 patients, occurred in 41% of cases. Female sex and diuretic use were identified as risk factors, but hypokalemia did not increase ICU transfer or mortality risk.
Area of Science:
- Internal Medicine
- Infectious Diseases
- Nephrology
Background:
- COVID-19 can lead to various clinical conditions causing electrolyte imbalances.
- Hypokalemia (low serum potassium) is a significant concern in COVID-19 patients, linked to severe complications.
- Understanding the prevalence, risk factors, and outcomes of hypokalemia in COVID-19 is crucial.
Purpose of the Study:
- To determine the prevalence of hypokalemia in hospitalized COVID-19 patients.
- To identify risk factors associated with hypokalemia in this patient cohort.
- To evaluate the association between hypokalemia and adverse outcomes such as ICU transfer and mortality.
Main Methods:
- Retrospective analysis of 290 non-ICU admitted COVID-19 patients.
- Data collected from February 16 to April 14, 2020, at a tertiary teaching hospital in Modena, Italy.
- Analysis included serum potassium levels, risk factor assessment, and outcome evaluation.
Main Results:
- Hypokalemia was detected in 41% of patients (119/290), with most cases being mild.
- Female sex (OR 2.44) and diuretic therapy (OR 1.94) were significant risk factors for hypokalemia.
- Hypokalemia was not associated with increased risk of ICU transfer (OR 0.52) or in-hospital mortality (OR 0.47).
Conclusions:
- Hypokalemia is a frequent electrolyte disorder in COVID-19 patients.
- Female sex and diuretic use are key risk factors for hypokalemia in COVID-19.
- In this cohort, hypokalemia was not linked to severe outcomes like ICU admission or death.
Background:
Patients with COVID-19 experience multiple clinical conditions that may cause electrolyte imbalances. Hypokalemia is a concerning electrolyte disorder closely associated with severe complications. This study aimed to estimate prevalence, risk factors and outcome of hypokalemia in a cohort of patients with confirmed COVID-19.
Methods:
A retrospective analysis was conducted on 290 non-ICU admitted patients with COVID-19 at the tertiary teaching hospital of Modena, Italy, from February 16 to April 14, 2020.
Results:
Hypokalemia was detected in 119 out of 290 patients (41%) during hospitalization. Mean serum potassium was 3.1 ± 0.1 meq/L. The majority of patients (90.7%) patients experienced only a mild decrease in serum potassium level (3-3.4 mEq/L). Hypokalemia was associated with hypocalcemia, which was detected in 50% of subjects. Urine potassium-to-creatinine ratio, measured in a small number of patients (n = 45; 36.1%), revealed an increase of urinary potassium excretion in most cases (95.5%). Risk factors for hypokalemia were female sex (odds ratio (OR) 2.44; 95% CI 1.36-4.37; P 0.003) and diuretic therapy (OR 1.94, 95% CI 1.08-3.48; P 0.027). Hypokalemia, adjusted for sex, age and SOFA score, was not associated with ICU transfer (OR 0.52; 95% CI 0.228-1.212; P = 0.131), in-hospital mortality (OR, 0.47; 95% CI 0.170-1.324; P = 0.154) and composite outcome of ICU transfer or in-hospital mortality (OR 0.48; 95% CI 0.222-1.047; P = 0.065) in our cohort of patients.
Conclusions:
Hypokalemia was a frequent disorder in subjects with COVID-19. Female sex and diuretic therapy were identified as risk factors for low serum potassium levels. Hypokalemia was unrelated to ICU transfer and death in this cohort of patients.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Myocarditis III: Medical Management
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Acute Kidney Injury VI: Nursing Management

